Q-omics provides the consensus-scored MIR17HG profile across patient tissues and cancer cell-line models. MIR17HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR17HG is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MIR17HG RNA expression shows 18,321 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, COAD, and BRCA as cancer lineages where MIR17HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR17HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR17HG survival associations across molecular data types. MIR17HG RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR17HG RNA expression–survival associations across cancer types. High MIR17HG expression shows unfavorable associations in UVM, ACC and PRAD, but favorable associations in UCS, BLCA and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR17HG RNA expression.
This table summarizes MIR17HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR17HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR17HG shows lower tumor expression in KICH, BRCA and KIRP and higher tumor expression in COAD, READ and STAD. The COAD box plot shows higher MIR17HG RNA expression in tumor versus normal tissue (log2 FC = +1.672, t-test p < 0.001).
This table shows molecular features associated with MIR17HG in patient tissues and cancer cell lines. In patient samples, MIR17HG shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
